Safety in these pediatric populations was consistent with the known safety profile across approved adult and pediatric indications1,2
States were also strongly advised to strictly monitor epidemiological profile of admitted COVID patients
73% have cited fears like losing eyesight, painful procedure or long recovery period when it comes to cataract surgeries
An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56.
Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patients
V116 designed to target serotypes that account for 85% of all invasive pneumococcal disease in individuals aged 65 and over in the United States as of 2019
Alliances with CVS Health and Javara further embed clinical research into the community healthcare setting, expanding access to patient populations across the U.S to increase diversity in clinical trials
48% of people are either hypertensive or at risk of becoming hypertensive & 30% of people have a high Waist Hip Ratio (WHR) – an early indication of the onset of CVDs
Increased and timely testing will enable early identification of COVID cases and help to curb spread of the infection among the community
Next-generation booster vaccine candidate demonstrates potential to protect against COVID-19 variants of concern, including Omicron BA.1 and BA.2, with a favorable safety and tolerability profile
Subscribe To Our Newsletter & Stay Updated
